1. Home
  2. DCGO vs SPRO Comparison

DCGO vs SPRO Comparison

Compare DCGO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DocGo Inc.

DCGO

DocGo Inc.

HOLD

Current Price

$0.96

Market Cap

136.0M

Sector

Health Care

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.20

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCGO
SPRO
Founded
2015
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Managed Health Care
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.0M
136.7M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
DCGO
SPRO
Price
$0.96
$2.20
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$3.33
$5.00
AVG Volume (30 Days)
878.9K
487.9K
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$368,093,385.00
$40,549,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$0.51
52 Week High
$5.68
$3.22

Technical Indicators

Market Signals
Indicator
DCGO
SPRO
Relative Strength Index (RSI) 40.78 41.80
Support Level $0.87 $2.28
Resistance Level $1.05 $2.42
Average True Range (ATR) 0.07 0.13
MACD 0.01 -0.03
Stochastic Oscillator 38.60 0.00

Price Performance

Historical Comparison
DCGO
SPRO

About DCGO DocGo Inc.

DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: